Introduction
Materials and methods
Patients and tissue samples
Immunohistochemistry analysis
Statistical analysis
Results
Overexpression of PAK2 and pSer20PAK2 in human gastric cancer tissues
Association of PAK2 and pSer20PAK2 expression with the clinicopathological characteristics of human gastric cancer
Features | No. of cases | PAK2 expression | P | pSer20PAK2 | P | ||
---|---|---|---|---|---|---|---|
High (%) | Low (%) | High (%) | Low (%) | ||||
Age (years)
| 82 | 65.32 ± 11.06 | 64.59 ± 11.88 | NS | 65.17 ± 11.29 | 64.99 ± 11.81 | NS |
Gender
| |||||||
Male | 56 | 42 (75.00) | 14 (25.00) | NS | 47 (83.93) | 9 (16.07) | NS |
Female | 26 | 20 (76.92) | 6 (23.08) | 22 (84.62) | 4 (15.38) | ||
Histopathological type
| |||||||
Intestina type
| |||||||
pap | 3 | 2 (66.67) | 1 (33.33) | NS | 2 (66.67) | 1 (33.33) | NS |
tub1 | 19 | 15 (78.95) | 4 (21.05) | 16 (84.21) | 3 (15.79) | ||
tub2 | 22 | 16 (72.73) | 6 (27.27) | 18 (81.82) | 4 (18.18) | ||
Diffuse type
| |||||||
por1 | 12 | 8 (66.67) | 4 (33.33) | NS | 10 (83.33) | 2 (16.67) | NS |
por2 | 26 | 21 (80.77) | 5 (19.23) | 23 (88.46) | 3 (11.54) | ||
Tumor depth (pT)
| |||||||
pT1 ~ pT2 | 62 | 42 (67.74) | 20 (32.26) | 0.022 | 49 (79.03) | 13 (20.97) | 0.036 |
pT3 ~ pT4 | 20 | 20 (100.00) | 0 (0) | 20 (100.00) | 0 (0) | ||
Lymph node metastasis (pN)
| |||||||
pN0 ~ pN1 | 66 | 46 (69.70) | 20 (30.30) | 0.022 | 53 (80.30) | 13 (19.70) | 0.036 |
pN2 ~ pN3 | 16 | 16 (100.00) | 0 (0) | 16 (100.00) | 0 (0) | ||
Distant metastasis (pM)
| |||||||
pM0 | 76 | 56 (73.68) | 20 (26.32) | 0.025 | 63 (82.89) | 13 (17.11) | 0.038 |
pM1 | 6 | 6 (100.00) | 0 (0) | 6 (100.00) | 0 (0) | ||
pStage
| |||||||
I ~ II | 59 | 39 (66.10) | 20 (33.90) | 0.018 | 46 (77.97) | 13 (33.90) | 0.031 |
III ~ IV | 23 | 23 (100.00) | 0 (0) | 23 (100.00) | 0 (0) | ||
Lymphatic invasion
| |||||||
Negative | 35 | 26 (74.29) | 9 (25.71) | NS | 29 (82.86) | 6 (17.14) | NS |
Positive | 47 | 36 (74.60) | 11 (25.40) | 40 (85.11) | 7 (14.89) | ||
Venous invasion
| |||||||
Negative | 58 | 42 (72.41) | 16 (17.59) | NS | 49 (84.48) | 9 (15.52) | NS |
Positive | 24 | 20 (83.33) | 4 (16.67) | 20 (83.33) | 4 (16.67) | ||
Hematogenous recurrence
| |||||||
Negative | 72 | 55 (76.39) | 17 (23.61) | NS | 61 (84.72) | 11 (15.28) | NS |
Positive | 10 | 7 (70.00) | 3 (30.00) | 8 (80.00) | 2 (20.00) | ||
Peritoneal recurrence
| |||||||
Negative | 72 | 55 (76.39) | 17 (23.61) | NS | 61 (84.72) | 11 (15.28) | NS |
Positive | 10 | 7 (70.00) | 3 (30.00) | 8 (80.00) | 2 (20.00) |
Overexpression of PAK2 and pSer20PAK2associate with unfavorable prognosis in human gastric cancer
Independent factors | Univariate P | Multivariate P | Hazard ratio | 95 % confidence interval |
---|---|---|---|---|
Tumor depth (pT)
| ||||
pT1 and pT2/pT3 and pT4 | <0.001 | 0.002 | 2.821 | 1.312 ~ 6.263 |
Lymph node metastasis (pN)
| ||||
Negative/positive | <0.001 | <0.001 | 7.292 | 2.575 ~ 26.327 |
Venous invasion
| ||||
Negative/positive | <0.001 | NS | 1.673 | 0.910 ~ 4.122 |
PAK2 expression
| ||||
Low/high | 0.001 | 0.012 | 3.681 | 1.274 ~ 11.066 |
pSer20PAK2 expression
| ||||
Low/high | 0.001 | 0.012 | 3.624 | 1.196 ~ 11.228 |